[go: up one dir, main page]

MX2018000239A - Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. - Google Patents

Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Info

Publication number
MX2018000239A
MX2018000239A MX2018000239A MX2018000239A MX2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A
Authority
MX
Mexico
Prior art keywords
formula
agents
bifosphonates
teranostic
hbed
Prior art date
Application number
MX2018000239A
Other languages
English (en)
Other versions
MX377208B (es
Inventor
F Kung Hank
Rye Choi Seok
Wu Zehui
Ploessl Karl
Zha Zhihao
Original Assignee
Five Eleven Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Eleven Pharma Inc filed Critical Five Eleven Pharma Inc
Publication of MX2018000239A publication Critical patent/MX2018000239A/es
Publication of MX377208B publication Critical patent/MX377208B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la formula I o formula II que son agentes de toma de imágenes óseas potenciales; ciertos compuestos etiquetados con 68Ga mostraron excelente captación y retención ósea; la presente invención también se refiere a composiciones farmacéuticas que comprenden un portador farmacéuticamente aceptable y un compuesto de formula I o formula II o una sal farmacéuticamente aceptable del mismo.(ver formula I y formula II).
MX2018000239A 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. MX377208B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US201662320296P 2016-04-08 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (2)

Publication Number Publication Date
MX2018000239A true MX2018000239A (es) 2018-05-23
MX377208B MX377208B (es) 2025-03-07

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000239A MX377208B (es) 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Country Status (12)

Country Link
US (1) US10253052B2 (es)
EP (1) EP3319643B1 (es)
JP (1) JP6792875B2 (es)
KR (1) KR102651945B1 (es)
CN (1) CN107847618B (es)
AU (1) AU2016289474C1 (es)
CA (1) CA2991498A1 (es)
DK (1) DK3319643T3 (es)
EA (1) EA201890221A1 (es)
IL (1) IL256726A (es)
MX (1) MX377208B (es)
WO (1) WO2017007790A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6792875B2 (ja) 2015-07-07 2020-12-02 ファイブ イレブン ファーマ インコーポレイテッド Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用
TW201832750A (zh) * 2017-03-02 2018-09-16 美商５１１製藥公司 放射性藥品標記裝置
WO2020028825A1 (en) * 2018-08-03 2020-02-06 Board Of Regents, The University Of Texas System Method for extraction and purification of 68ga
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
WO2021067513A1 (en) * 2019-10-01 2021-04-08 City Of Hope Metal chelating agents and methods of using the same
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329623T1 (de) * 2001-10-22 2006-07-15 Dow Global Technologies Inc Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
BRPI0409063A (pt) * 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
US7161000B2 (en) 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9044468B2 (en) * 2007-06-26 2015-06-02 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
JP5690733B2 (ja) * 2009-08-20 2015-03-25 富士フイルムＲｉファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体
WO2012139912A1 (en) * 2011-04-13 2012-10-18 Firmenich Sa Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6792875B2 (ja) 2015-07-07 2020-12-02 ファイブ イレブン ファーマ インコーポレイテッド Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用

Also Published As

Publication number Publication date
CN107847618B (zh) 2021-07-16
US10253052B2 (en) 2019-04-09
JP6792875B2 (ja) 2020-12-02
EP3319643A4 (en) 2019-04-10
DK3319643T3 (da) 2020-06-15
HK1254864A1 (en) 2019-07-26
AU2016289474C1 (en) 2021-04-08
CA2991498A1 (en) 2017-01-12
EA201890221A1 (ru) 2018-06-29
MX377208B (es) 2025-03-07
JP2018524352A (ja) 2018-08-30
CN107847618A (zh) 2018-03-27
AU2016289474A1 (en) 2018-02-01
US20170022224A1 (en) 2017-01-26
KR102651945B1 (ko) 2024-03-26
WO2017007790A9 (en) 2018-01-04
IL256726A (en) 2018-03-29
AU2016289474B2 (en) 2020-12-24
WO2017007790A1 (en) 2017-01-12
EP3319643B1 (en) 2020-04-22
EP3319643A1 (en) 2018-05-16
KR20180026736A (ko) 2018-03-13

Similar Documents

Publication Publication Date Title
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
ZA201906832B (en) Novel psma-binding agents and uses thereof
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
MX375570B (es) Conjugados de pirrolobenzodiazepina
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2017005199A (es) Conjugados y reactivos de conjugacion.
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
MX376122B (es) Composiciones de plinabulina.
GEAP202014748A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX394833B (es) Formulaciones con mejora de la estabilidad.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.

Legal Events

Date Code Title Description
FG Grant or registration